Latham Represents Acino in Acquisition of Takeda Primary Care Portfolio

London team advised on cross-border pharmaceutical carve-out M&A deal.

October 16, 2019

Acino and Takeda Pharmaceuticals have signed an agreement for Acino to acquire parts of Takeda’s primary care portfolio in selected countries in the Middle East and Africa, and in Ukraine, for a total value in excess of US$200 million.

As part of this acquisition, Acino will acquire the rights to selected pain management, gastroenterology, cardiovascular and respiratory products from Takeda’s prescription pharmaceutical and OTC portfolio. The agreement will enable Acino to reinforce its position in the following key markets: United Arab Emirates, Egypt, Saudi Arabia, Turkey, Ukraine and South Africa, as well as several other countries.

Additionally, both parties will enter into a multi-year manufacturing and supply agreement, under which Takeda will continue to manufacture the products on behalf of Acino. The acquisition is subject to approvals by the relevant authorities and is expected to close during January – March 2020.

Latham advised Acino on the transaction with a deal team led by London corporate partners Robbie McLaren and Farah O’Brien, with associates Samantha Peacock, Stephanie Dellosa, Antonina Semyachkova, Zoe Liu, and Daria Les. Advice was also provided on technology matters by London partner Fiona Maclean and associate Mihail Krepchev, on benefits, compensation & employment by partner Stephen Brown, and on life sciences and regulatory matters by associate Frances Stocks Allen.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.